Proteomic analysis of cerebrospinal fluid of amyotrophic lateral sclerosis patients in the presence of autologous bone marrow derived mesenchymal stem cells

• Published in: Stem cell research & therapy Vol. 15; no. 1; pp. 301 - 18
• Main Authors: Reis, Ana Luiza Guimarães, Maximino, Jessica Ruivo, Lage, Luis Alberto de Padua Covas, Gomes, Hélio Rodrigues, Pereira, Juliana, Brofman, Paulo Roberto Slud, Senegaglia, Alexandra Cristina, Rebelatto, Carmen Lúcia Kuniyoshi, Daga, Debora Regina, Paiva, Wellingson Silva, Chadi, Gerson
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.09.2024; BioMed Central; BMC
• Subjects: Adult; Aged; Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - cerebrospinal fluid; Amyotrophic Lateral Sclerosis - metabolism; Amyotrophic Lateral Sclerosis - therapy; Analysis; Apolipoprotein A-I - cerebrospinal fluid; Apolipoprotein A-I - metabolism; Apolipoproteins; Apolipoproteins E - cerebrospinal fluid; Apolipoproteins E - genetics; Apolipoproteins E - metabolism; Bone Marrow Cells - metabolism; Care and treatment; Cerebrospinal fluid; Development and progression; Female; Fibrin; Humans; Male; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchymal Stem Cells - metabolism; Middle Aged; Protein Interaction Maps; Protein-protein interaction network; Protein-protein interactions; Proteomics; Proteomics - methods; Stem cells; Transplantation; Transplantation, Autologous; Amyotrophic lateral sclerosis; Protein-protein interaction network; Cerebrospinal fluid; Proteomics; Mesenchymal stem cells

Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressive motoneuron degenerative disorder. There are still no drugs capable of slowing disease evolution or improving life quality of ALS patients. Thus, autologous stem cell therapy has emerged as an alternative treatment regime to be in...